Early-Stage Drug Development Is Strategic Infrastructure. Can The US Afford To Lose It? So-Yeon KangandYunan Ji September 17, 2026

https://www.healthaffairs.org/content/forefront/early-stage-drug-development-strategic-infrastructure-can-us-afford-lose The globalization of biopharmaceutical innovation is likely to continue. The central challenge therefore is whether the US can use the heightened competition as a catalyst to strengthen its domestic ecosystem.